Human HIV-1 Monoclonal Antibody | anti-HIV-1 antibody

HIV-1 (C5 (gp120)) Human Monoclonal Antibody (670-30D)

Cat. Num. AAA588188

• Reactivity: HIV-1
• Applications: ELISA, Flow Cytometry, Functional Assay
• Synonyms: HIV-1; Monoclonal Antibody; HIV-1 (C5 (gp120)) Human Monoclonal Antibody (670-30D); anti-HIV-1 antibody

• Host: Human
• Reactivity: HIV-1
• Clonality: Monoclonal
• Isotype: lgG3 lambda
• Clone Number: 670-30D
• Specificity: The antibody recognizes the C5 region of the HIV-1 protein gp120. (amino acids 495-516)
• Form/Format: Lyophilized protein G purified in PBS pH7.4

• Applicable Applications for anti-HIV-1 antibody: ELISA (EIA), Flow Cytometry (FC/FACS)
• Application Notes: Reconstitute with deionized water. Optimal dilution has to be determined by the user.
• Immunogen: This antibody was generated from HIV-infected individuals by a method based on the Epstein-Barr virus transformation of peripheral blood mononuclear cells (PBMCs) followed by fusion with heteromyeloma cells.
• Preservative: None
• Preparation and Storage: Lyophilized antibodies can be kept at 4ºC for up to 3 months and should be kept at -20 degree C for long-term storage (2 years). To avoid freeze-thaw cycles, reconstituted antibodies should be aliquoted before freezing for long-term (1 year) storage (-80 degree C) or kept at 4 degree C for short-term usage (2 months). For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made with the assay buffer. After the maximum long-term storage period (2 years lyophilized or 1 year reconstituted) antibodies should be tested in your assay with a standard sample to verify if you have noticed any decrease in their efficacy.

Related Product Information for anti-HIV-1 antibody

Of the two types of Human immunodeficiency virus (HIV) which have been characterized, HIV-1 is more infective and is prevalent globally. The HIV virion is encapsulated by a viral envelope that contains complexes of surface proteins, which are important for the virus to attach and fuse to infect target cells. A precursor molecule known as gp160 (glycoprotein 160) is cleaved by proteases into gp120 (glycoprotein 120) and gp41 (glycoprotein 41), glycoproteins that make up the envelope proteins of HIV. The gp120 protein is composed of five variable regions (V1-V5) which often form loop structures, and five constant regions (C1-C5). The C5 region comprises the carboxy terminus of gp120 and shares sequence similarity with HLA (human leukocyte antigen) class I and II molecules.

References

1. Gorny MK-Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. 2. Nyambi PN-Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. 3. Gorny MK and Zolla-Pazner S-Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human. 4. Gigler A-Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. 5. Zolla-Pazner S-Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV. 6. Gorny MK-A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades. 7. Nyambi PN-Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness. 8. Gorny MK-Human monoclonal antibodies to the V3 loop of HIV-1 with intra-and interclade cross-reactivity. 9. Hioe CE-Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. 10. Zolla-Pazner S-Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.